1. Home
  2. ENVB

ENVB

Enveric Biosciences Inc.

Logo Enveric Biosciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Founded: 1994 Country:
United States
United States
Employees: N/A City: NAPLES
Market Cap: 6.6M IPO Year: N/A
Target Price: $10.00 AVG Volume (30 days): 4.5M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.09 EPS Growth: N/A
52 Week Low/High: $0.65 - $6.98 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: